Evidence map›Paper›PMID 35756165›Full record

ArticleNon-coding RNA research2022

miR-204-5p in vivo inhibition cause diminished CD45RO cells rate in lungs of melanoma B16-bearing mice.

Nadezhda Palkina, Mariya Aksenenko, Danil Zemtsov, Semyon Lavrentev, Ivan Zinchenko, Vasiliy Belenyuk, Andrey Kirichenko, Andrey Savchenko, Tatiana Ruksha

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Non-coding RNA research, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 93% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Omics in Cutaneous Melanoma.Asian Pacific journal of cancer prevention : APJCP · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Nadezhda PalkinaDepartment of Pathophysiology, Krasnoyarsk State Medical University, Krasnoyarsk, 660022, Russia.
Mariya AksenenkoDepartment of Pathophysiology, Krasnoyarsk State Medical University, Krasnoyarsk, 660022, Russia.
Danil ZemtsovDepartment of Pathophysiology, Krasnoyarsk State Medical University, Krasnoyarsk, 660022, Russia.
Semyon LavrentevDepartment of Pathophysiology, Krasnoyarsk State Medical University, Krasnoyarsk, 660022, Russia.
Ivan ZinchenkoDepartment of Pathophysiology, Krasnoyarsk State Medical University, Krasnoyarsk, 660022, Russia.
Vasiliy BelenyukLaboratory of Cell Molecular Physiology and Pathology, Federal Research Center, Krasnoyarsk Science Center of The Siberian Branch of The Russian Academy of Sciences, Krasnoyarsk, 660022, Russia.
Andrey KirichenkoDepartment of Pathological Anatomy, Krasnoyarsk State Medical University, Krasnoyarsk, 660022, Russia.
Andrey SavchenkoLaboratory of Cell Molecular Physiology and Pathology, Federal Research Center, Krasnoyarsk Science Center of The Siberian Branch of The Russian Academy of Sciences, Krasnoyarsk, 660022, Russia.
Tatiana RukshaDepartment of Pathophysiology, Krasnoyarsk State Medical University, Krasnoyarsk, 660022, Russia.
Krasnoyarsk State Medical University · RUKrasnoyarsk Scientific Center · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The treatment of melanoma remains a challenge, despite novel approaches recently becoming available for disseminated tumors. RNA targeting is being intensively studied in various types of disease. The aim of the present study was to explore whether the in vivo use of a microRNA (miR)-204-5p inhibitor affected melanoma progression, and whether its metastasis affects target organ remodeling. CD45RO

Indexed as

ApoptosisCD45ROMelanoma B16microRNA LNA inhibitormiR-204-5pmiR-211

Identifiers

PMID35756165
PMCPMC9188961
OpenAlexW4281779073

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.